In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given ...

Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more ...